

**Mothers' antiphospholipid antibodies during pregnancy and the relation to offspring outcome**

A. Mekinian *et al.*

**Supplementary data**

**Table I.** Mothers characteristics and neonatal outcome.

Mothers' characteristics	n=133
Age (years)	36±5
Primary APS	108 (81%)
Treatment during pregnancy	
Aspirin and low-molecular weight heparin	18 (90%)
Corticosteroids	25 (19%)
Hydroxychloroquine	15 (11%)
Pregnancy outcome	
Gestational hypertension / diabetes	12 (9%) / 14 (11%)
Intrauterine growth restriction	12 (9%)
Preeclampsy / Hellp syndrome	3 (2%)
Neonates' outcome	
Birth weight (kg)	3020±5
Height (cm)	48±3
Cranial perimeter (cm)	34±2
Neonates' complications	18 (13%)
Infections	5 (4%)

Values are means with SD and numbers with frequencies. APS: antiphospholipid syndrome.

**Table II.** Antiphospholipid antibodies in mothers during pregnancy.


	1 <sup>st</sup> trimester (n=87)	2 <sup>nd</sup> trimester (n=46)	3 <sup>rd</sup> trimester (n=46)
Lupus anticoagulant (n;%)	16 (18%)	6 (13%)	6 (13%)
Anticardiolipin IgG	34 (39%)	23 (50%)	11 (24%)
Anticardiolipin IgG (UGPL)	36 ± 114	31 ± 54	23 ± 43
Anticardiolipin IgM	9 (10%)	1 (2%)	2 (4%)
Anticardiolipin IgM (UMPL)	5 ± 5	6 ± 8	6 ± 12
Anti-β2GPI IgG	22 (25%)	10 (22%)	5 (11%)
Anti-β2GPI IgG (UGPL)	7 ± 11	6 ± 7	11 ± 28
Anti-β2GPI IgM	19 (22%)	10 (22%)	4 (10%)
Anti-β2GPI IgM (UMPL)	7 ± 11	6 ± 7	3 ± 4

Values are means with standard deviation and numbers with frequencies.


**Table III.** Mothers antiphospholipid antibodies levels during pregnancy regarding neonates' complications.

	1 <sup>st</sup> trimester	2 <sup>nd</sup> trimester	3 <sup>rd</sup> trimester
Anticardiolipin IgG (-)	50 ± 162	24 ± 29	15 ± 30
Anticardiolipin IgG (+)	21 ± 26	47 ± 83	35 ± 56
Anticardiolipin IgM (-)	7 ± 10	5 ± 6	4 ± 4
Anticardiolipin IgM (+)	4 ± 6	4 ± 5	6 ± 11
Anti-β2GPI IgG (-)	13 ± 33	7 ± 12	4 ± 8
Anti-β2GPI IgG (+)	6 ± 31	6 ± 9	8 ± 13
Anti-β2GPI IgM (-)	4 ± 7	6 ± 8	6 ± 8
Anti-β2GPI IgM (+)	2 ± 4	4 ± 4	3 ± 3

(-) : absence of neonates' complications; (+): presence of neonates' complications.



**Fig. 1.** Mothers' antiphospholipid antibodies evolution during pregnancy.



**Fig. 2.** Mothers' anticardiolipin IgG antibodies evolution during pregnancy regarding the neonates' complications.